Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

ABSTRACT: Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

PROVIDER: PRJEB29267 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition

Project description:Targeted next-generation sequencing was performed in patients with IDH1 or IDH2 mutations. Here we describe 4 cases where mutant IDH isoform switching serves as a mechanism of acquired clinical resistance to mutant IDH inhibition.

2018-10-24 | PRJEB29344 | EVA

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Project description:Somatic mutations in cytosolic or mitochondrial isoforms of isocitrate dehydrogenase (IDH1 or IDH2, respectively) contribute to oncogenesis via production of the metabolite 2-hydroxyglutarate (2HG). Isoform-selective IDH inhibitors suppress 2HG production and induce clinical responses in patients with IDH1- and IDH2-mutant malignancies. Despite the promising activity of IDH inhibitors, the mechanisms that mediate resistance to IDH inhibition are poorly understood. Here, we describe four clinical cases that identify mutant IDH isoform switching, either from mutant IDH1 to mutant IDH2 or vice versa, as a mechanism of acquired clinical resistance to IDH inhibition in solid and liquid tumors. SIGNIFICANCE: IDH-mutant cancers can develop resistance to isoform-selective IDH inhibition by "isoform switching" from mutant IDH1 to mutant IDH2 or vice versa, thereby restoring 2HG production by the tumor. These findings underscore a role for continued 2HG production in tumor progression and suggest therapeutic strategies to prevent or overcome resistance.This article is highlighted in the In This Issue feature, p. 1494.

| S-EPMC6699636 | biostudies-literature

Project description:Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition

| PRJEB29344 | ENA

Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas

Project description:Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas

| PRJNA922456 | ENA

Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas [RNA-Seq]

Project description:The brain tumor immune microenvironment (TIME) continuously evolves during glioma progression, but only a limited view of a highly complex glioma associated immune contexture across isocitrate dehydrogenase mutation (IDH) classified gliomas is known. Herein, we present an unprecedentedly comprehensive view of myeloid and lymphoid cell type diversity with our m-RNA sequencing interrogation.

2024-06-23 | GSE222518 | GEO

Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas [scRNA-seq]

2024-06-23 | GSE222520 | GEO

Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas [RNA-Seq]

Project description:Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas [RNA-Seq]

| PRJNA922462 | ENA

Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas [scRNA-seq]

Project description:Immune landscape of Isocitrate Dehydrogenase (IDH) stratified human gliomas [scRNA-seq]

| PRJNA922463 | ENA

Hepatic transcriptomics reveals that lipogenesis is a key signaling pathway in isocitrate dehydrogenase 2 deficient mice

Project description:The present study was conducted to capture signatures of isocitrate dehydrogenase 2 deficient (Idh2-/-) mice liver transcriptome using mRNA sequencing technique which provides information to discover new transcripts and to quantify transcript levels. Using this mRNA sequencing results, bioinformatic analyses will be performed to further identify key biological functions of Idh2 influencing disease-related signaling pathways.

2020-03-10 | GSE128361 | GEO

Isoform switching events in esophageal adenocarcinoma progression

Project description:Isoform switching events in esophageal adenocarcinoma progression

| PRJNA798444 | ENA